Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(2):199–213. doi: 10.1111/j.1527-3458.2001.tb00195.x

Ondansetron: A Selective 5‐HT3 Receptor Antagonist and Its Applications in CNS‐Related Disorders

Jiang‐Hong Ye 1,✉, Rex Ponnudurai 1, Rebecca Schaefer 1
PMCID: PMC6741689  PMID: 11474424

ABSTRACT

Ondansetron is a selective 5‐hydroxytryptamine3 (5‐HT3) receptor antagonist that has been introduced to clinical practice as an antiemetic for cancer treatment‐induced and anesthesia‐related nausea and vomiting. Its use under these circumstances is both prophylactic and therapeutic. It has a superior efficacy, safety and pharmacoeconomic profile compared with other groups of antiemetics, namely antidopaminergics, antihistamines and anticholinergics. However, its place in the management of anticipatory and delayed vomiting in cancer treatment and as a rescue antiemetic in surgical patients needs to be further explored. Furthermore, recent animal and human research also reflects its possible novel application in the treatment of other disease states, such as alcoholism, cocaine addiction, opioid withdrawal syndrome, anxiety disorders, gastrointestinal motility disorders, Tourette's syndrome and pruritus. This review revisits the widespread physiological and pathological effects of 5‐HT and discusses both the basic science literature and the clinical developments responsible for the conventional and novel uses of ondansetron. In addition, new discoveries relating to the effects of ondansetron on other receptors/channels and their possible therapeutic applications are presented.

Keywords: Alcoholism, Antiemetics, 5‐Hydroxytryptamine3 antagonist, Ondansetron, Serotonin receptors

Full Text

The Full Text of this article is available as a PDF (142.3 KB).

References

  • 1. Andrews PLR, Bailey HE, Hawthorn J, Stables R, Tyers MB. GR38032F, a novel 5‐HT3‐receptor antagonist, can both abolish emesis induced by cyclophosphamide or radiation in the ferret. Br J Pharmacol 1987;91(Suppl): 417P. [Google Scholar]
  • 2. Andrews PRL, Davis CJ. The mechanism of emesis induced by anticancer therapies In: Andrews PRL, ed. Emesis in anticancer therapy: Mechanisms and treatment. London : Chapman and Hall Medical, 1993:113–161. [Google Scholar]
  • 3. Andrews PLR, Hawthorn J. Evidence for an extra‐abdominal site of action for the 5‐HT3‐receptor antagonist BRL24924 in the inhibition of radiation‐evoked emesis in the ferret. Neuropharmacology 1987;26:1367–1370. [DOI] [PubMed] [Google Scholar]
  • 4. . Anonymous :ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729–764. [DOI] [PubMed] [Google Scholar]
  • 5. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827–831. [DOI] [PubMed] [Google Scholar]
  • 6. Barnes NM, Sharp T. A review of central 5‐HT receptors and their function. Neuropharmacology 1999;38:1083–152. [DOI] [PubMed] [Google Scholar]
  • 7. Betz H. Ligand‐gated ion channels in the brain: The amino acid receptor superfamily. Neuron 1990;5:383–392. [DOI] [PubMed] [Google Scholar]
  • 8. Boast C, Bartolomeo AC, Morris H, Moyer JA. 5‐HT antagonists attenuate MK801‐impaired radial arm maze performance in rats. Neurobiol Learn Mem 1999;71:259–271. [DOI] [PubMed] [Google Scholar]
  • 9. Bock M, Sinner B, Gottlicher M, Martin E, Motsch J. Dolasetron prevents postanesthetic shivering. Anesthesiology 1999;91:A1184. [Google Scholar]
  • 10. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine‐induced pruritus. Anesthesiology 1999;90:432–436. [DOI] [PubMed] [Google Scholar]
  • 11. Bosek V, Hu P, Robinson LA. Acute myocardial ischemia after administration of ondansetron hydrochloride. Anesthesiology 2000;92:885–887. [DOI] [PubMed] [Google Scholar]
  • 12. Bradley PB, Engel G, Feniuk W et al. Proposals for the classification and nomenclature of functional receptors for 5‐hydroxytryptamine. Neuropharmacology 1986;25:563–576. [DOI] [PubMed] [Google Scholar]
  • 13. Broocks A, Briggs NC, Pigott TA, et al. Behavioral, physiological and neuroendocrine responses in healthy volunteers to μ‐chlorophenylpiperazine (m‐CPP) with and without ondansetron pretreatment. Psychopharmacology (Berl) 1997;130:91–103. [DOI] [PubMed] [Google Scholar]
  • 14. Bunce KT, Tyers MB. The role of 5‐HT in postoperative nausea and vomiting. Br J Anaesth 1992;69 (Suppl 1): 60S–62S. [DOI] [PubMed] [Google Scholar]
  • 15. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. Pharmacological properties of GR38032F, a novel antagonist at 5‐HT3 receptors. Br J Pharmacol 1988;94:397–412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Castejon AM, Cubeddu LX. Level of punishment determines anticonflict activity of ondansetron in pigeons: Comparison with buspirone and diazepam. Pharmacol Biochem Behav 1998;61:451–457. [DOI] [PubMed] [Google Scholar]
  • 17. Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid‐induced emesis in post‐surgical adult patients. Ondansetron OIE Post‐Surgical Study Group. Eur J Anaesthesiol 1999;16:669–677. [DOI] [PubMed] [Google Scholar]
  • 18. Clayton BD, Thomas RE. Nausea and vomiting In: Herfindal ET, ed. Clinical pharmacy and therapeutics. Philadelphia , PA : Williams & Wilkins, 1992:424–430. [Google Scholar]
  • 19. Costall B, Domeney AM, Gunning SJ, Naylor RJ, Tattershall FD, Tyers MB. GR38032F, a novel inhibitor of cisplatin‐induced emesis in the ferret. Br J Pharmacol 1988;94:397–4l2. 2969267 [Google Scholar]
  • 20. Cunningham RS. 5‐HT3 receptor antagonists: A review of pharmacology and clinical efficacy. Oncology Nursing Forum 1997;24:33–40. [PubMed] [Google Scholar]
  • 21. Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994;5:461–469. [DOI] [PubMed] [Google Scholar]
  • 22. Fabling JM, Gan TJ, El‐Moalem HE, Warner DS, Borel CO. A randomized double‐blind comparison of ondansetron, droperidol and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. Anesth Analg 2000;91:358–361. [DOI] [PubMed] [Google Scholar]
  • 23. Goldberg PA, Kamm MA, Setti‐Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel stndrome by 5‐HT3 antagonism (ondansetron). Digestion 1996;57:478–483. [DOI] [PubMed] [Google Scholar]
  • 24. Gregory RE, Ettinger DS. 5‐HT3‐receptor antagonists for the prevention of chemotherapy‐induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173–189. [DOI] [PubMed] [Google Scholar]
  • 25. Hasler WL. Serotonin receptor physiology: Relation to emesis. Dig Dis Sci 1999;44(Suppl 8): 108S–113S. [PubMed] [Google Scholar]
  • 26. Hoyer D, Clarke DE, Fozard JR et al. International union of pharmacology classification of receptors for 5‐hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157–203. [PubMed] [Google Scholar]
  • 27. Johnson BA, Ait‐Daoud N. Medications to treat alcoholism. Alcohol Res Health 1999;23:99–106. [PMC free article] [PubMed] [Google Scholar]
  • 28. Johnson BA, Ait‐Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl) 2000;149:327–334. [DOI] [PubMed] [Google Scholar]
  • 29. Johnson BA, Roache JD, Javors MA et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000;284:963–971. [DOI] [PubMed] [Google Scholar]
  • 30. Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000;14:33–40. [DOI] [PubMed] [Google Scholar]
  • 31. Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994;49:6–10. [DOI] [PubMed] [Google Scholar]
  • 32. King GR, Xiong Z, Douglass S, Ellinwood EH. Long‐term blockade of the expression of cocaine sensitizationby ondansetron, a 5‐HT3‐receptor antagonist. Eur J Pharmacol 2000;394:97–101. [DOI] [PubMed] [Google Scholar]
  • 33. King GR, Xiong Z, Ellinwood EH Jr. Blockade of cocaine sensitization and tolerance by the co‐administration of ondansetron, a 5‐HT3 receptor antagonist, and cocaine. Psychopharmacology (Berl) 1997;130:159–65. [DOI] [PubMed] [Google Scholar]
  • 34. Klein RL, Sanna E, McQuilkin SJ, Whiting PJ, Harris RA. Effects of 5‐HT3‐receptor antagonists on binding and function of mouse and human GABAA receptors. Eur J Pharmacol 1994;268:237–246. [DOI] [PubMed] [Google Scholar]
  • 35. Kovac Al. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000;59:213–243. [DOI] [PubMed] [Google Scholar]
  • 36. Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid‐induced pruritus: A role for 5‐HT3 antagonists Br J Anaesth 1999;82:439–441. [DOI] [PubMed] [Google Scholar]
  • 37. Lovinger DM. 5‐HT3 receptors and the neural actions of alcohols: An increasingly exciting topic. Neurochem Int 1999;35:125–30. [DOI] [PubMed] [Google Scholar]
  • 38. Manullang TR, Viscomi CM, Pace NL. Intrathecal fentanyl is superior to intravenous ondansetron for the prevention of perioperative nausea during cesarean delivery with spinal anesthesia. Anesth Analg 2000;90:1162–1166. [DOI] [PubMed] [Google Scholar]
  • 39. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5‐hydroxytryptamine3 antagonist ondansetron with high dose metoclopramide in the control of cisplatin‐induced emesis. N Engl J Med 1990;322:816–821. [DOI] [PubMed] [Google Scholar]
  • 40. Mathew RJ, Wilson WH. Evaluation of the effects of diazepam and an experimental anti‐anxiety drug on regional cerebral blood flow. Psychiatry Res 1991;40:125–134. [DOI] [PubMed] [Google Scholar]
  • 41. Maxton DG, Morris J, Whorwell PJ. Selective 5‐hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia Aliment Pharmacol Ther 1996;10:595–599. [DOI] [PubMed] [Google Scholar]
  • 42. McBride WJ, Li TK. Animal models of alcoholism: Neurobiology of high alcohol‐drinking behavior in rodents. Crit Rev Neurobiol 1998;12:339–369. [DOI] [PubMed] [Google Scholar]
  • 43. McCann UD, Morgan CM, Geraci M, Slate SO, Murphy DL, Post RM. Effects of the 5‐HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 1997;17:360–369. [DOI] [PubMed] [Google Scholar]
  • 44. Melamed E, Friedberg G, Zoldan J. Psychosis: Impact on the patient and family. Neurology 1999;52:S14–16. [PubMed] [Google Scholar]
  • 45. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5‐hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo‐controlled, double‐blind cross‐over trial. Eur J Gastroenterol Hepatol 1998;10:865–870. [DOI] [PubMed] [Google Scholar]
  • 46. Murphy M, Carmichael AJ. Renal itch. Clin Exp Dermatol 2000;25:103–106. [DOI] [PubMed] [Google Scholar]
  • 47. Naylor RJ, Inall FC. The physiology and pharmacology of postoperative nausea and vomiting. Anaesthesia 1994;49(Suppl): 2–5. [DOI] [PubMed] [Google Scholar]
  • 48. Page IH. Serotonin (5‐hydroxytryptamine). Physiol Rev 1954;34:563–588. [DOI] [PubMed] [Google Scholar]
  • 49. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high‐dose chemotherapy with transplantation: Report on a retrospective analysis of a 5‐HT3 regimen and literature review. Support Care Cancer 1999;7:413–424. [DOI] [PubMed] [Google Scholar]
  • 50. Pinelli A, Trivulzio S, Tomasoni L. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. Eur J Pharmacol 1997;340:111–119. [DOI] [PubMed] [Google Scholar]
  • 51. Pollard BJ. Pharmacology of neuromuscular blocking drugs In: Harper NJN, ed. Muscle relaxants in anaesthesia. London : Arnold Edward, 1995:13–25. [Google Scholar]
  • 52. Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double‐blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high‐dose upper abdominal irradiation. Clin Oncol 1990;2:71–75. [DOI] [PubMed] [Google Scholar]
  • 53. Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy. Can J Anaesth 1999;46:40–44. [DOI] [PubMed] [Google Scholar]
  • 54. Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open‐field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 1998;59:677–683. [DOI] [PubMed] [Google Scholar]
  • 55. Roberts LJ, Oates JA. Disorders of vasodilator hormones: The carcinoid syndrome and mastocytosis In: Wilson JD, ed. Williams text‐book of endocrinology. Philadelphia , PA : W. B. Saunders Company, 1992:1619–1625. [Google Scholar]
  • 56. Roila F, Ballatori E, Tonato M, Del Favero A. 5‐HT3‐receptor antagonists: Differences and similarities. Eur J Cancer 1997;33:1364–1370. [DOI] [PubMed] [Google Scholar]
  • 57. Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM. A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol 1998;18:121–131. [DOI] [PubMed] [Google Scholar]
  • 58. Roychoudhury M, Kulkarni SK. Antianxiety profile of ondansetron, a selective 5‐HT3 antagonist, in a novel animal model. Methods Find Exp Clin Pharmacol 1997;19:107–111. [PubMed] [Google Scholar]
  • 59. Russell D, Kenny GNC. 5‐HT3 antagonists in postoperative nausea and vomiting. Br J Anaesth 1992;69:63S–68S. [DOI] [PubMed] [Google Scholar]
  • 60. Schreiber R, Melon C, De Vry J. The role of 5‐HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 1998;135:383–391. [DOI] [PubMed] [Google Scholar]
  • 61. Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic‐induced tardive dyskinesia. Am J Psychiatry 2000;157:287–289. [DOI] [PubMed] [Google Scholar]
  • 62. Sniadach MS, Alberts MS. A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. Anesth Anal 1997;85:797–800. [DOI] [PubMed] [Google Scholar]
  • 63. Stables R, Andrews PLR, Bailey HE, et al. Antiemetic properties of the 5‐HT3‐receptor antagonist, GR38032F. Cancer Treat Rev 1987;14:333–336. [DOI] [PubMed] [Google Scholar]
  • 64. Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer‐Beecher T, Noll D. Intravenous ondansetron for the control of opioid‐induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther 1999;21:1216–1227. [DOI] [PubMed] [Google Scholar]
  • 65. Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999;14:373–376. [DOI] [PubMed] [Google Scholar]
  • 66. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. Br Med J 1997;314:1088–1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Tramer MR, Phillips C, Reynolds DG, McQuay HJ, Moore RA. Cost‐effectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 1999;54:226–234. [DOI] [PubMed] [Google Scholar]
  • 68. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5‐HT3 receptor research. Eur J Pharmacol 1990;188:301–312. [DOI] [PubMed] [Google Scholar]
  • 69. Watcha MF. The cost‐effective management of postoperative nausea and vomiting. Anesthesiology 2000;92:931–933. [DOI] [PubMed] [Google Scholar]
  • 70. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773–794. [DOI] [PubMed] [Google Scholar]
  • 71. Ye JH, Hunt T, Wu WH, McArdle JJ. Ondansetron modulates GABAA current of rat central nervous system neurons. Eur J Pharmacol 1997;337:87–94. [DOI] [PubMed] [Google Scholar]
  • 72. Ye JH, Mui WC, Ren J, Hunt TE, Wu WH, Zbuzek VK. Ondansetron exhibits the properties of a local anesthetic. Anesth Analg 1997;85:1116–1121. [DOI] [PubMed] [Google Scholar]
  • 73. Ye JH, Schaefer R, Wu WH, Liu PH, Zbuzek VK, McArdle JJ. Inhibitory effect of ondansetron on glycine response of dissociated rat hippocampal neurons. J Pharmacol Exp Ther 1999;290:104–111. [PubMed] [Google Scholar]
  • 74. Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine‐induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000;91:172–175. [DOI] [PubMed] [Google Scholar]
  • 75. . Zofran (ondansetron hydrochloride) and clinical pharmacology In: Zofran Product Information, released by Glaxo Wellcome, Research Triangle Park , NC . October, 1999. [Google Scholar]
  • 76. . Zofran (ondansetron hydrochloride) and dosage adjustment in patients with hepatic dysfunction In: Zofran Product Information, released by Glaxo Wellcome, Research Triangle Park , NC . October 1999. [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES